12:00 AM
 | 
Apr 21, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Peroxisome proliferation activated receptor γ coactivator 1α (PPARGC1A; PGC-1α); nicotinamide adenine dinucleotide (NAD+)

Renal disease

INDICATION: Renal damage

Mouse studies suggest promoting PPARGC1A expression or the NAD+ precursor nicotinamide could help treat acute kidney injury (AKI). In a mouse model of renal ischemia, overexpression of PPARGC1A in the...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >